Last reviewed · How we verify
RO5093151
At a glance
| Generic name | RO5093151 |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). (PHASE1)
- A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers (PHASE1)
- A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease (PHASE1)
- A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma (PHASE2)
- A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO5093151 CI brief — competitive landscape report
- RO5093151 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI